Asset Valuation

Many of our clients come to us when they need a basis for making investment and divestment decisions on new drug and medical products, projects and technologies.

Catenion offers the pharmaceutical and medical products industries’ best-in-class assessment of such opportunities, along the dimensions of both value and risk.

Catenion’s R&D Suite of Tools, Processes and Methods for Asset Valuation

R&D Risk Assessment: An expert system with more than 600 criteria measuring a project’s risk level against industry average, differentiated by drug format (small molecules, monoclonal antibodies, recombinant proteins, etc) and stage of the R&D process. Based on the input of hundreds of industry experts and used to evaluate more than 700 projects to date.

Option Space Mapping: A systematic approach to mapping out the development options of a project based on hard biological, chemical, and preclinical data regarding the target, the client’s own compound, competitor compounds, the market situation, and the project’s position in the pipeline.

Innovativeness Screening: A method developed to assess market attractiveness for early compounds before proof of concept. Used instead of more elaborate forecasting methods. Key dimensions are novelty, usefulness, theoretical market potential and exploitability by company.

Competitiveness Modelling: An elaborate forecasting tool developed by Catenion for post-proof-of-concept compounds. The tool permits rating of product features against those of current and expected competitors, and forecasts the whole market segment rather than just one company’s compound.

Value–at–Risk Monte Carlo Simulation: Portfolio values based on risk–adjusted expected values are not risk–free, as every practitioner knows. Our approach shows the level of unacceptable risk (i.e. the likelihood of not reaching a minimum level of return) a company incurs with its portfolio and how to reduce this risk by adjusting the portfolio.